Daclatasvir combined with peginterferon-α and ribavirin for the treatment of chronic hepatitis C: a meta-analysis

Daclatasvir, a HCV NS5A inhibitor, is a new direct-acting antiviral drug for chronic hepatitis C (CHC). This study aimed to evaluate the efficacy and safety of daclatasvir combined with peginterferon-α (pegIFN-α) and ribavirin (RBV) for the treatment of CHC. The databases of PUBMED, EMBASE, COCHRANE...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Qin, Li, Kang, Cao, Ming Rong, Bie, Cai Qun, Tang, Hui Jun, Tang, Shao Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5023653/
https://www.ncbi.nlm.nih.gov/pubmed/27652142
http://dx.doi.org/10.1186/s40064-016-3218-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5023653/
https://www.ncbi.nlm.nih.gov/pubmed/27652142
http://dx.doi.org/10.1186/s40064-016-3218-x

Ejemplares similares